Core Insights - Eton Pharmaceuticals has licensed U.S. marketing rights for an ultra-rare disease product candidate, which is expected to be the first and only generic alternative for a treatment impacting fewer than 100 patients in the U.S. [1][2] Company Overview - Eton Pharmaceuticals focuses on developing and commercializing treatments for rare diseases, currently offering eight commercial products and five additional candidates in late-stage development [3]. Product Development and Pipeline - The newly licensed product is under FDA review and is anticipated to be approved and launched in mid-2026, contributing to Eton's goal of expanding its ultra-rare disease product portfolio [2][5]. - The company aims to enhance patient and provider experiences through its Eton Cares patient support program, leveraging past successes with existing products [2].

Core Insights - Eton Pharmaceuticals is set to participate in the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, at 9:30 AM ET in New York City [1] Company Overview - Eton Pharmaceuticals focuses on developing and commercializing treatments for rare diseases, currently offering eight commercial products [2] - The company's commercial rare disease products include KHINDIVI™, INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone [2] - Eton has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800, and ZENEO hydrocortisone autoinjector [2]

Core Insights - Eton Pharmaceuticals is participating in the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025, in New York, where its executive leadership will host 1x1 meetings [1] Company Overview - Eton Pharmaceuticals focuses on developing and commercializing treatments for rare diseases, currently offering eight commercial products for rare diseases [3] - The company's commercial products include KHINDIVI™, INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone [3] - Eton has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800, and ZENEO hydrocortisone autoinjector [3]

Core Viewpoint - Eton Pharmaceuticals, Inc. will report its third quarter 2025 financial results on November 6, 2025, and will host a conference call to discuss these results [1]. Company Overview - Eton Pharmaceuticals is focused on developing and commercializing treatments for rare diseases, currently offering eight commercial products for rare diseases [3]. - The company's commercial products include KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone [3]. - Eton has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800, and ZENEO® hydrocortisone autoinjector [3]. Investor Engagement - Management will take live questions during the conference call and will also answer emailed questions from investors [2]. - The live webcast of the conference call will be accessible on Eton's website, with an archived version available for 30 days after the event [2].

Group 1 - Eton Pharmaceuticals, Inc is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases [3] - The company currently has eight commercial rare disease products, including KHINDIVI™, INCRELEX, and Nitisinone [3] - Eton has five additional product candidates in late-stage development, such as ET-600 and ZENEO hydrocortisone autoinjector [3] Group 2 - Eton's executive leadership team will host 1x1 meetings at the 2025 Wells Fargo Healthcare Conference from September 3-5, 2025 in Boston, MA [1] - Interested parties can schedule a meeting by contacting their Wells Fargo institutional sales representative [2]

Company Overview - Eton Pharmaceuticals, Inc is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases [3] - The company currently has eight commercial rare disease products, including KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone [3] - Eton has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800, and ZENEO® hydrocortisone autoinjector [3] Upcoming Financial Results - Eton Pharmaceuticals will report its second quarter 2025 financial results on August 7, 2025 [1] - Management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results [1] - Investors can submit questions via email during the conference call [1]

Company Overview - Eton Pharmaceuticals, Inc is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases [3] - The company currently has seven commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone [3] - Eton has six additional product candidates in late-stage development: ET-400, ET-600, Amglidia, ET-700, ET-800, and ZENEO hydrocortisone autoinjector [3] Upcoming Events - Eton's CEO, CFO, and Chief Business Officer will participate in two upcoming investor conferences [1] - The 25th Annual B. Riley Securities Investor Conference is scheduled for May 22, 2025, at 11:15 am ET in Marina Del Rey, California [5] - The 22nd Annual Craig-Hallum Institutional Investor Conference will take place on May 28, 2025, in Minneapolis, Minnesota [5]

Core Viewpoint - Eton Pharmaceuticals, Inc. will report its first quarter 2025 financial results on May 13, 2025, and will host a conference call to discuss these results [1]. Company Overview - Eton Pharmaceuticals is focused on developing and commercializing treatments for rare diseases, currently offering seven commercial products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone [3]. - The company has six additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, ET-700, ET-800, and ZENEO® hydrocortisone autoinjector [3]. Investor Relations - Investors can submit questions via email to investorrelations@etonpharma.com during the conference call [1]. - The live webcast of the conference call will be accessible on Eton's website, with an archived version available for 30 days post-event [2].